DANBURY, Conn., April 29 /PRNewswire-FirstCall/ -- Biodel Inc. today announced that its second quarter fiscal year 2008 financial results will be released on Friday, May 9, 2008. Following the issuance of its financial results, Biodel’s senior management team will host a conference call to discuss second quarter results and provide an update on the Company’s developments.
Interested parties may access a live audio webcast of the conference call in the investor section of Biodel’s website at www.biodel.com. The audio webcast will be archived and available for replay at the same location.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel’s product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company’s lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel’s pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company’s website at www.biodel.com.
CONTACT: Investors, Rebecca Der, rder@burnsmc.com, or Media, Carney
Noensie, cnoensie@burnsmc.com, both of Burns McClellan, Inc.,
+1-212-213-0006, for Biodel Inc.
Web site: http://www.biodel.com/
